secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001437749-25-025417
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q2 revenue $11.4M, net loss $3.8M; raises FY2025 revenue guidance to $50-52M
--------------------------------------------------------------------------------

- Q2 total revenue $11.4M vs $12.1M YoY; Advanced Energy flat at $9.7M, OEM down 28.5% to $1.7M.
- Net loss attributable to stockholders $3.8M ($0.09/shr) vs $6.6M ($0.19/shr) YoY; adjusted EBITDA loss $2.0M vs $4.3M.
- Soft launch of AYON Body Contouring System exceeding expectations; commercial launch planned September 2025.
- Renuvion launched in China via partner GlamMoon; initial procedures completed with strong clinical interest.
- FY2025 revenue guidance raised to $50-52M (from $47.6-49M); Advanced Energy guidance $42-44M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000143774925025417/0001437749-25-025417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000143774925025417/apyx20250526_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-025417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer